Kyntra Bio, Inc. (KYNB)

Kyntra Bio, Inc. (KYNB) — VMCI valuation read

KYNB screens at VMCI 54/100, a 4-point gap above the Healthcare sector median (50). For a mid-cap Kyntra Bio, Inc. share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

KYNB has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: KYNB trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -0.6x leaves covenant headroom, which sets the rate-cycle exposure for Kyntra Bio, Inc..

KYNB rose 0.9% over the trailing 7 days, with a -5.4% read on a 30-day basis.